Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zai Lab Ltd ADR (NQ: ZLAB )

28.96 -2.13 (-6.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Earnings Scheduled For November 12, 2024
Via Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
From Zai Lab Limited
Via Business Wire
Zai Lab, A Top 6% Stock, Launched To A 16-Month High On Its 'Impressive' Results
The company is working on an antibody drug conjugate, which is like a smart bomb for cancer cells. 
Via Investor's Business Daily
UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in November and December Investor Conferences
From Zai Lab Limited
Via Business Wire
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
From Zai Lab Limited
Via Business Wire
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
From Zai Lab Limited
Via Business Wire
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
Why Is Zynex (ZYXI) Stock Down 24% Today?
Zynex stock is falling on Friday as ZYXI investor react to earnings misses and poor guidance for Q3 and the full year of 2024. 
Via InvestorPlace
Topics Earnings
Exposures Financial
Why Is DexCom (DXCM) Stock Down 38% Today?
DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance. 
Via InvestorPlace
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem
A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock. 
Via InvestorPlace
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
From Zai Lab Limited
Via Business Wire
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
From Zai Lab Limited
Via Business Wire
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
From Zai Lab Limited
Via Business Wire
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Participation in May and June Investor Conferences
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.